Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci,
enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality …

Abstract Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone
chemically distinct from currently marketed fluoroquinolones with the absence of a …

Introduction: Despite advances in modern medicine, severe community-acquired
pneumonia (CAP) continues to be a potentially deadly disease. Mortality rate reaches up to …

Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute
bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive …

Fluoroquinolones have been in clinical use for over 50 years with significant efficacy.
However, increasing resistance and emergence of some marked adverse events have …

Delafloxacin (ABT 492) is a new fluoroquinolone available in both oral and parenteral
formulations. It has recently been approved by the Food and Drug Administration for the …

Delafloxacin (DLX) is a new fluoroquinolone pending approval, which has shown a good in
vitro and in vivo activity against major pathogens associated with skin and soft tissue …

CAP continues to be an important infection because of its impact on patient outcomes
especially in the elderly and immunocompromised hosts. The availability of new antibiotics …

Introduction: Community-acquired pneumonia is the most common infection leading to
hospitalization and death in all age groups, especially in elderly populations. Increasing …

The extensive use of fluoroquinolones has been consequently accompanied by the
emergence of bacterial resistance, which triggers the necessity to discover new compounds …